108 BioCapital
108 BioCapital is a US-based private equity growth-stage fund investing in biotech and medtech companies addressing unmet medical needs. Led by Dr. Sasha Bakhru, the fund provides growth capital and operational expertise to innovative healthcare companies, having closed over $40M at first close in February 2026.
- Company typePrivate
- Founded-
- Headquarters—
- Headcount1–10
- GTM typeB2B
- OfferingServices
What 108 BioCapital does
108 BioCapital is a US-based private equity growth-stage fund that invests in innovative biotech and medtech companies developing transformative healthcare solutions. The fund, operating under the legal name 108 BioCapital Growth Stage Fund, is led by Founder & CEO Dr. Sasha Bakhru, a biotechnologist and entrepreneur who is the inventor or co-inventor of drug discoveries including Ciraparantag and Amylyx, both of which were successfully commercialized. The fund targets growth-stage companies addressing significant unmet medical needs, with the underlying market thesis citing US healthcare spending projected to reach 20% of GDP by 2032.
The fund's business model is a traditional private equity growth-equity structure: it raises capital from accredited investors through a private placement memorandum and deploys that capital into portfolio companies, generating revenue through management fees and future carried interest upon successful exits. As of February 2026, the fund had achieved a first close of over $40 million and made its inaugural investment of $20 million in Pinwheel Therapeutics to fund Phase 2b clinical trials of Ciraparantag, a next-generation universal anticoagulant reversal agent positioned to address a market gap following the withdrawal of Andexxa from the US market in December 2025. The fund is backed by Ranjan Pai and has initiated registration for a Gift City feeder vehicle to access international limited partners.
The fund's competitive positioning rests on its leadership team's combined scientific, operational, and investment expertise, supported by a senior advisory bench spanning regulatory affairs, intellectual property law, biopharma commercialization, and legal structuring. The team operates with a small core staff (1–10 employees) augmented by advisors with backgrounds at Johnson & Johnson, Bristol-Myers Squibb, Pfizer, and other major healthcare organizations, providing portfolio companies with regulatory, clinical, and go-to-market guidance alongside growth capital.
108 BioCapital firmographics
Firmographics- Name
- 108 BioCapital
- Legal name
- 108 BioCapital Growth Stage Fund
- Website
- https://108.bio
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- 108 BioCapital is a US-based private equity growth-stage fund investing in biotech and medtech companies addressing unmet medical needs. Led by Dr. Sasha Bakhru, the fund provides growth capital and operational expertise to innovative healthcare companies, having closed over $40M at first close in February 2026.
- Ownership category
- akta.pro rank
108 BioCapital industry classification
Industry- Product category
- Healthcare Private Equity
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Security Brokers, Dealers & Flotation Companies (6211), Services-Commercial Physical & Biological Research (8731)
- akta.pro industry
- Consortia & Defined Microbial Community TherapeuticsHealth & Medical Research Grantmaking Foundations
Keywords
108 BioCapital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
108 BioCapital product offering
Product offeringCore offering
108 BioCapital is a US-based private equity fund that provides growth-stage capital to innovative biotech and medtech companies addressing significant unmet medical needs. The fund combines deep scientific expertise with investment acumen to identify, nurture, and scale high-potential healthcare opportunities, with its inaugural $20 million commitment to Pinwheel Therapeutics supporting Phase 2b clinical trials for Ciraparantag, a universal anticoagulant reversal agent.
Product overview
108 BioCapital operates as a single private equity fund focused on biotech and medtech investments. The fund targets innovative companies addressing urgent unmet medical needs, combining deep scientific expertise with investment acumen to identify and scale high-potential opportunities. The company was founded by Dr. Sasha Bakhru, who previously invented or co-invented drug discoveries including Ciraparantag and Amylyx, both successfully commercialized, and created the first PoC Coagulometer for anticoagulant therapy monitoring.
Differentiator
Problem solved
Functional benefit
Products and services
- 108 BioCapital Growth Stage Fund A US-based private equity fund that invests growth-stage capital in innovative biotech and medtech companies addressing significant unmet medical needs; offered exclusively to accredited investors via private placement memorandum.
Companies that use 108 BioCapital
Customer profileSegments1 record
Ideal customer profiles2 records
108 BioCapital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
108 BioCapital partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights4 records
108 BioCapital competitors and assessment
Company assessmentDirect peers
- RA Capital Management: RA Capital is a healthcare-focused crossover fund manager investing in publicly and privately held biotech and medical device companies. Its growth-stage biotech investing model is closely comparable to 108 BioCapital's mandate.
- ARCH Venture Partners: ARCH Venture Partners is a leading biotech-focused venture capital firm investing in early-stage and growth-stage life sciences companies. Its scientific-founder orientation and biotech-only focus mirror 108 BioCapital's approach.
- Baker Bros. Advisors: Baker Bros. Advisors is a dedicated biotech-focused long-only manager investing across stages in life sciences companies. Its biotech-only mandate and scientific-analyst-led approach parallels 108 BioCapital's thesis.
- 5AM Ventures: 5AM Ventures is an early-stage life sciences venture capital firm investing in biotech companies. Its specialist life sciences mandate and stage overlap makes it a relevant comparable to 108 BioCapital.
- Atlas Venture: Atlas Venture is a life sciences-focused venture capital firm building and funding biotech companies from inception through clinical development. Its specialist biotech focus parallels 108 BioCapital's mandate and stage.
- Frazier Healthcare Partners: Frazier Healthcare Partners is a dedicated healthcare PE/VC firm investing across therapeutics, medical devices, and biotech at multiple stages. Its healthcare-only focus and growth-stage fund structure make it a direct peer.
- OrbiMed: OrbiMed is one of the largest dedicated healthcare-focused investment firms globally, investing across biopharma, medical devices, and diagnostics at all stages. Its healthcare-only mandate and growth-equity emphasis directly parallels 108 BioCapital's focus.
- Perceptive Advisors: Perceptive Advisors is a healthcare-focused investment firm managing credit and equity strategies in biotech and medical devices. Its growth-stage healthcare investing and willingness to back clinical assets is highly comparable to 108 BioCapital.
Regional players
- Sofinnova Partners: Sofinnova Partners is a European venture capital firm dedicated to life sciences including biotech and medtech. Its specialist life sciences focus parallels 108 BioCapital's mandate, though it primarily operates in Europe rather than the US.
Broad incumbents
- New Enterprise Associates (NEA): NEA is a large multi-stage venture capital firm with a dedicated healthcare practice investing across biotech, medical devices, and digital health. While broader than 108 BioCapital, its healthcare growth-stage practice is comparable.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
108 BioCapital social profiles
Digital presence108 BioCapital financial estimates
Financial estimateRevenue estimate
Valuation estimate
108 BioCapital leadership team
Management profileNumber of profiles
Profiles11 records
108 BioCapital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
108 BioCapital M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 108 BioCapital
What does 108 BioCapital do?
108 BioCapital is a US-based private equity fund that provides growth-stage capital to innovative biotech and medtech companies addressing significant unmet medical needs. The fund combines deep scientific expertise with investment acumen to identify, nurture, and scale high-potential healthcare opportunities, with its inaugural $20 million commitment to Pinwheel Therapeutics supporting Phase 2b clinical trials for Ciraparantag, a universal anticoagulant reversal agent.
Is 108 BioCapital a public or private company?
108 BioCapital is a private company. It is classified as venture growth investor backed and is currently operating.
When was 108 BioCapital founded?
108 BioCapital was founded in -1. It employs 1 to 10 people.
Who are 108 BioCapital's main competitors?
Direct peers on record are RA Capital Management, ARCH Venture Partners, Baker Bros. Advisors, 5AM Ventures, Atlas Venture, Frazier Healthcare Partners, OrbiMed and Perceptive Advisors. Sofinnova Partners is listed as a regional player. New Enterprise Associates (NEA) is listed as a broad incumbent.
Does 108 BioCapital have an API?
No public API is recorded for 108 BioCapital.
What industry is 108 BioCapital in?
108 BioCapital's product category is Healthcare Private Equity. Its primary akta.pro industry code is HLAAAFAC, Consortia & Defined Microbial Community Therapeutics, with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 541714 and its SIC code is 6211.